We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+60.74%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.09B
AUM Growth
+$121M
Cap. Flow
-$94.6M
Cap. Flow %
-8.7%
Top 10 Hldgs %
62.33%
Holding
35
New
2
Increased
10
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$30M
2
DNLI icon
Denali Therapeutics
DNLI
+$9.99M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$7.37M
4
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$6.2M
5
CDNA icon
CareDx
CDNA
+$4.59M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$83.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$21.2M
3
SAGE
Sage Therapeutics
SAGE
+$20.9M
4
QTTB icon
Q32 Bio
QTTB
+$14.8M
5
EDIT icon
Editas Medicine
EDIT
+$9.44M

Sector Composition

Rank Sector Weight
1 Healthcare 91.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
1
Sarepta Therapeutics
SRPT
$1.63B
$86.5M 7.95%
670,000
-210,000
-24% -$21.2M
BLUE
2
DELISTED
bluebird bio
BLUE
$85.1M 7.83%
74,884
+27,599
+58% +$30M
CDXS icon
3
Codexis
CDXS
$157M
$81.1M 7.46%
5,073,780
– –
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$75.3M 6.92%
940,000
– –
MYOK
5
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$73.2M 6.74%
1,005,000
-110,000
-10% -$6.67M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$29.1B
$59.3M 5.45%
515,000
-85,000
-14% -$8.47M
NVTA
7
DELISTED
Invitae Corporation
NVTA
$58.7M 5.4%
3,638,388
-200,000
-5% -$3.54M
CNST
8
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$57.1M 5.25%
1,212,734
-311,226
-20% -$8.99M
BOLD
9
DELISTED
Audentes Therapeutics, Inc
BOLD
$51.5M 4.73%
860,000
– –
FATE icon
10
Fate Therapeutics
FATE
$294M
$49.9M 4.59%
2,550,000
– –
DNTH icon
11
Dianthus Therapeutics
DNTH
$5.72B
$47M 4.32%
193,633
+3,125
+2% +$584K
BLFS icon
12
BioLife Solutions
BLFS
$1.56B
$39.9M 3.67%
2,468,571
+40,000
+2% +$650K
AGIO icon
13
Agios Pharmaceuticals
AGIO
$1.84B
$39.4M 3.62%
825,000
-110,000
-12% -$4.16M
CDNA icon
14
CareDx
CDNA
$2.48B
$25.9M 2.38%
1,200,000
+200,000
+20% +$4.59M
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
$23.8M 2.19%
300,000
– –
DNLI icon
16
Denali Therapeutics
DNLI
$3.67B
$21.8M 2%
1,250,000
+600,000
+92% +$9.99M
FULC icon
17
Fulcrum Therapeutics
FULC
$280M
$20.6M 1.9%
1,239,285
+395,000
+47% +$3.78M
ILMN icon
18
Illumina
ILMN
$30.2B
$19.9M 1.83%
61,680
– –
GRTS
19
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$19.4M 1.78%
2,160,000
+390,000
+22% +$3.25M
ALEC icon
20
Alector
ALEC
$168M
$18.5M 1.71%
1,076,039
+265,000
+33% +$4.5M
SAGE
21
DELISTED
Sage Therapeutics
SAGE
$16.6M 1.53%
230,000
-170,000
-43% -$20.9M
GNMK
22
DELISTED
GenMark Diagnostics, Inc
GNMK
$16.2M 1.49%
3,365,000
– –
DCPH
23
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$15.9M 1.46%
255,000
+155,000
+155% +$7.37M
VYGR icon
24
Voyager Therapeutics
VYGR
$179M
$15.3M 1.4%
1,095,075
-33,000
-3% -$480K
ADPT icon
25
Adaptive Biotechnologies
ADPT
$3.71B
$13.9M 1.27%
463,125
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Casdin Capital held 35 positions worth $1.09B, up 13% from $966M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Casdin Capital withdrew a net $94.6M in Q4 2019, closing 3 positions and reducing 8 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $83.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Bristol-Myers Squibb Company Contingent Value Rights worth $4.51M.

  • Casdin Capital's largest Q4 2019 buy was Bristol-Myers Squibb Company Contingent Value Rights: 1,500,000 shares worth $4.51M.
  • Casdin Capital added most to bluebird bio in Q4 2019, an estimated $30M increase.
  • Casdin Capital's biggest Q4 2019 reduction was Sarepta Therapeutics, cutting an estimated $21.2M.
  • Casdin Capital fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $83.7M.
  • Casdin Capital's ten largest holdings make up 62% of its $1.09B portfolio in Q4 2019.
  • Casdin Capital opened 2 new positions and closed 3 in Q4 2019.
  • Casdin Capital's portfolio value rose 13% quarter-over-quarter to $1.09B.

Based on Casdin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.